Literature DB >> 12425141

[Metastatic esthesioneuroblastoma. Challenge in interdisciplinary combined modality therapy].

M Koch1, M Koester, A Schänzer, J Constantinidis, H Iro.   

Abstract

Esthesioneuroblastoma is a rare tumor, which in many cases is diagnosed at an advanced stage with an high recurrence rate and incidence of metastases. Regionary metastases predict a poor prognosis. There is no standard therapy approach for these tumors. The most widly accepted primary therapy is radical craniofacial enbloc resection followed by radiation therapy. Today chemotherapy is getting more important and is administered with curative intention. Multidisciplinary management results in significantly longer survival in advanced tumor stages and recurrence. A clinical staging system as well as histopathological grading according of Hyams could be from importance for selection and timing of the different therapeutic modalities. We present a case of a 34-year-old female patient who was diagnosed with an advanced olfactory neuroblastoma of the upper nasal cavity with bilateral cervical lymph node metastasis (modified Kadish-stage D). Craniofacial resection and bilateral neck dissection was performed, followed by postoperative radiotherapy. Reviewing the recent literature the different therapeutic approaches are compared and discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12425141     DOI: 10.1007/s00106-001-0582-8

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  2 in total

1.  [Unilateral protrusion of the eyeball. A 21-year-old patient with a 3-week painless right-sided protrusion of the eyeball].

Authors:  J Dawczynski; J Walther; K Henning; W A Kaiser; J Strobel
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

Review 2.  [Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland].

Authors:  M Damm; A Temmel; A Welge-Lüssen; H E Eckel; M-P Kreft; J P Klussmann; H Gudziol; K-B Hüttenbrink; T Hummel
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.